AstraZeneca (AZN)
(Delayed Data from NSDQ)
$78.26 USD
+0.24 (0.31%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $78.32 +0.06 (0.08%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$78.26 USD
+0.24 (0.31%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $78.32 +0.06 (0.08%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth B Momentum C VGM
Zacks News
Pharma Stock Roundup: FDA Blow for AGN, Label Expansion Nod for MRK, BMY Cancer Drugs
by Zacks Equity Research
Allergan (AGN) gets CRL for uterine fibroids candidate, Esmya. Merck (MRK) and Bristol-Myers' (BMY) PD-L1 inhibitors get FDA approval for expanded labels.
Novartis Breast Cancer Drug Meets Primary Goal in Phase III
by Zacks Equity Research
Novartis' (NVS) late-stage candidate, BYL719, meets primary endpoint in SOLAR trial on advanced breast cancer patients.
Ironwood's Linzess Gets Approval in Japan for New Indication
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) along with its partner Astellas Pharma announces approval of Linzess in Japan for a new indication - chronic constipation.
Japan Nods to AstraZeneca's Tagrisso for First-Line NSCLC
by Zacks Equity Research
AstraZeneca (AZN) receives approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the label expansion of Tagrisso.
Merck, Eisai Get FDA Approval for Lenvima Label Expansion
by Zacks Equity Research
Merck (MRK) and Japanese partner Eisai gains an FDA approval for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for the first line treatment of unresectable HCC.
Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication
by Zacks Equity Research
Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.
Top Research Reports for Cisco, AstraZeneca & Enbridge
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems (CSCO), AstraZeneca (AZN) and Enbridge (ENB).
Ironwood Rides on Linzess' Progress, Stalls Lenisurad Drugs
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company announces restructuring initiative to improve operational efficiency.
Here's Why Merck (MRK) Stock is Up Since Q2 Earnings Release
by Zacks Equity Research
Merck's (MRK) stock is up 4.2% since announcement of earnings in July. Let us have a look at the reasons for the same.
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novo Nordisk, J&J, Allergan, Editas, AstraZeneca, Merck and Bristol-Myers
Pharma Stock Roundup: NVO Q2 Earnings, JNJ, AGN & AZN's Pipeline Updates in Focus
by Zacks Equity Research
Novo Nordisk (NVO) reports strong Q2 results. J&J (JNJ) seeks approval for new dosing regimen of multiple myeloma drug. Allergan (AGN) exercises option to buy Editas' lead ocular candidate.
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) product purchases and introductions in the Rx segment are expected to boost sales.
Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.
Pharma Stock Roundup: PFE Dominates Headlines, BMY Drug Gets EU Approval
by Zacks Equity Research
Pfizer (PFE) reports strong second-quarter results. European Commission approves Pfizer and Bristol-Myers' (BMY) medicines.
TESARO (TSRO) Misses Earnings and Revenue Estimates in Q2
by Zacks Equity Research
TESARO (TSRO) misses estimates for both earnings and revenues in the second quarter but beats on revenues. Zejula sales increase.
Drug Stocks to Report Q2 Earnings on Jul 31: PFE, INCY, ECYT
by Zacks Equity Research
Let's see how pharma/biotech stocks are poised ahead of their scheduled results on Jul 31.
Pharma Stock Roundup: LLY, AGN Post Solid Q2 Results, ABBV's Elagolix Gets FDA Nod
by Zacks Equity Research
Earnings are in focus this week with Lilly (LLY), Allergan (AGN) and Glaxo (GSK) delivering strong Q2 numbers. AbbVie (ABBV) gains FDA approval for Elagolix.
Merck (MRK) Q2 Earnings & Sales Top on Keytruda Strength
by Zacks Equity Research
Merck (MRK) beat estimates for both earnings and sales in second-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.
AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up
by Zacks Equity Research
AstraZeneca (AZN) beats earnings and sales estimates in the second quarter on the back of strong new product sales and maintains previously issued outlook for 2018.
AstraZeneca Sells Atacand's European Rights to Cheplapharm
by Zacks Equity Research
AstraZeneca (AZN) sells Atacand and Atacand Plus' European rights to Cheplapharm Arzneimittel for $210 million.
Ironwood Begins New Phase III Study to Expand Linzess Label
by Zacks Equity Research
Ironwood (IRWD) commences a phase IIIb study in order to add a couple of new symptoms like bloating and discomfort associated with IBS-C to Linzess' label.
Novartis Looks to Exit Antibacterial, Antiviral Program
by Zacks Equity Research
Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
by Zacks Equity Research
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
Biogen's Alzheimer Disease Candidate Succeeds in Phase II
by Zacks Equity Research
Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.
Clovis Gets EU Acceptance for Rubraca Label Expansion Filing
by Zacks Equity Research
Clovis Oncology's (CLVS) regulatory application seeking label expansion of Rubraca as maintenance treatment was accepted for review in Europe.